Structure and mechanism of the human TMEM260 O-mannosyltransferase

This study presents the first cryo-EM structures of the human O-mannosyltransferase TMEM260 in complex with its substrates, elucidating the molecular mechanism of O-mannosylation for critical cell guidance receptors and providing a structural basis for understanding associated congenital disorders.

The Gist

Imagine your body is a massive, high-tech factory. Inside this factory, proteins are the workers and machines that keep everything running. But for these proteins to work correctly, they often need "badges" or "tags" attached to them. One of the most important types of tags is called O-mannose. Think of it as a specific ID card that tells the protein where to go, how to fold, and how to talk to other cells.

If the factory loses the ability to attach these ID cards, the workers (proteins) get confused, break down, or end up in the wrong place. This causes serious diseases, including heart defects and neurological disorders.

For a long time, scientists knew that this tagging happened, but they didn't know how the machine doing the tagging actually worked. They were looking at a locked door without a key.

This paper is the moment the door finally opens. Here is the story of what the scientists discovered, explained simply:

1. The Mystery Machine: TMEM260

The scientists focused on a specific machine in the factory called TMEM260. This machine is a "glycosyltransferase," which is a fancy word for a "tag-attaching robot."

• The Problem: We knew this robot existed, but we didn't know what it looked like or how it grabbed the tag (the sugar) and stuck it onto the protein.
• The Breakthrough: Using a super-powerful microscope called Cryo-EM (which is like taking a 3D X-ray of a frozen molecule), the scientists finally took a clear picture of the robot.

2. The Robot's Design: A Molecular "Hand"

When they looked at the structure, they saw something amazing. The robot looks like a giant, mechanical hand emerging from the factory floor (the cell membrane).

• The Wrist (The Anchor): The bottom part of the robot is embedded in the wall of the factory. It holds the "donor" tag (a sugar molecule called Dol-P-Man) like a tool in a holster.
• The Palm: The middle part of the hand is the "workbench." This is where the magic happens.
• The Fingers: The top part has long, finger-like structures that reach out to grab the protein that needs tagging.

3. How the Robot Works: A Three-Step Dance

The scientists captured the robot in three different poses to see how it works:

1. Holding the Tag: First, they saw the robot holding the sugar tag in its "wrist." The tag is ready to go.
2. Grabbing the Target: Next, they saw the robot grab a long, floppy piece of a protein (like a loose thread). The "fingers" of the robot wrap around this thread to hold it steady.
3. The Snap (The Transfer): Finally, they saw the robot in action. The "palm" of the hand twists slightly. It grabs the sugar tag from the wrist and snaps it onto the specific spot on the protein thread.

The "Aha!" Moment:
The scientists realized this robot doesn't wait for the protein to be fully built and folded. Instead, it grabs the protein while it is still being made (like a tailor stitching a suit while the fabric is still on the loom). This is called co-translational glycosylation. It's a high-speed assembly line process!

4. Why This Matters: Fixing the Factory

The paper explains why this matters for human health:

• The ID Card System: This specific robot (TMEM260) is responsible for tagging a very important group of proteins involved in cell communication (like the "plexin" and "cMET" receptors). These are the proteins that tell cells how to move, where to grow, and how to build the heart and brain.
• The Broken Machine: The paper shows that when people have mutations (broken blueprints) in the gene for this robot, the "fingers" can't grab the protein, or the "palm" can't snap the tag on.
• The Result: Without these tags, the heart and brain don't develop correctly. This leads to a rare but severe condition called SHDRA syndrome, which causes heart defects and high infant mortality.

The Big Picture Analogy

Imagine you are building a complex LEGO castle.

• The Proteins are the LEGO bricks.
• The O-mannose tag is a special sticker you must put on specific bricks to make them fit together correctly.
• TMEM260 is the robot arm that applies the sticker.

Before this paper, we knew the robot existed, but we didn't know how its gears turned. Now, we have the instruction manual for the robot. We can see exactly how it grabs the brick, picks up the sticker, and sticks it on.

Why is this good news?
Now that we have the "blueprint" of the robot, scientists can:

1. Understand exactly why certain genetic mutations break the machine.
2. Design new drugs or therapies that might help fix the robot or bypass the broken parts.
3. Potentially prevent or treat the severe heart and brain defects caused by this missing tag.

In short, this paper takes a mysterious, invisible process and turns it into a clear, visual story of a molecular machine doing its job, giving us a new roadmap to fix human diseases.

Technical Summary

1. Problem Statement

Protein O-linked mannose (O-Man) glycosylation is critical for mammalian development, with defects leading to severe congenital disorders of glycosylation (CDG), including muscular dystrophies, neurological defects, and cardiac malformations. While the biosynthetic pathways for O-Man initiation are known to involve three enzyme families (POMT1/2, TMTC1–4, and TMEM260), the structural basis for how these enzymes recognize donors and acceptors, and the mechanism of the initial mannose transfer, remained unknown. Specifically, TMEM260 is responsible for O-mannosylating semaphorin plexin receptors and receptor tyrosine kinases (cMET, RON), and its loss causes SHDRA syndrome (structural heart defects and renal anomalies). The lack of structural data hindered the mechanistic understanding of substrate specificity and the interpretation of disease-causing mutations.

2. Methodology

The authors employed an integrated structural biology and biochemical approach:

• Cryo-Electron Microscopy (Cryo-EM): The study determined high-resolution structures of human TMEM260 in three distinct states:
  1. Binary Complex (Donor-bound): With the synthetic donor analogue farnesyl-phosphate-β-mannose (Far-P-Man) at 2.7 Å resolution.
  2. Binary Complex (Endogenous Donor-bound): With the natural donor dolichyl-phosphate-β-mannose (Dol-P-Man) captured during purification at 2.9 Å resolution.
  3. Ternary Complex (Donor + Acceptor-bound): With Dol-P-Man and a fluorescently labeled peptide derived from the PLXNB2 receptor (IPT1 domain) at 3.1 Å resolution.
• Biochemical Assays:
  • Peptide Binding: Used luminal domain fragments (Rossmann-like and TPR domains) fused to fluorescent proteins to test binding to synthetic peptides via pull-down assays and MALDI-TOF.
  • Cellular Reporter Assays: Utilized glycoengineered HEK293 cells (WT, TMEM260 knockout, and catalytically inactive D52A knock-in) expressing sfGFP reporters fused to PLXNB2 or RON peptides to verify O-mannosylation specificity.
  • Mutagenesis: Systematic alanine scanning of conserved residues in the transmembrane and luminal domains to assess catalytic activity using an ecto-cMET reporter and mass spectrometry.
• Glycoproteomics: LC-MS/MS analysis to map O-mannosylation sites and quantify site occupancy in cellular reporters.

3. Key Contributions and Results

A. Structural Architecture: The "Molecular Hand"

• Overall Fold: TMEM260 adopts a unique "molecular hand" architecture. It consists of:
  • A GT-C "wrist": A transmembrane module of 11 helices (TMHs 1–11) that anchors the enzyme in the ER membrane and binds the lipid-linked donor.
  • A "palm": An ER-luminal Rossmann-like (Rl) domain (residues 416–564) containing the catalytic center.
  • "Fingers": A distal Tetratricopeptide-repeat (TPR) domain (residues 565–706) that projects from the palm.
• Donor Binding: The natural donor Dol-P-Man (and analogue Far-P-Man) binds within a hydrophobic tunnel formed by the transmembrane helices. The sugar moiety sits at the membrane-lumen interface, poised for transfer.
• Acceptor Recognition: The TPR "fingers" and Rl "palm" form a continuous groove that binds extended, unfolded peptide substrates. The structure reveals that TMEM260 recognizes a specific acceptor sequon within the Immunoglobulin-like fold, Plexin, Transcription-factors (IPT) domains. The proposed signature is a long motif: P-x-x-x-x-x-P-x-x-x-G-P-x-x-G/A-G-G-x-x-T/S.

B. Mechanism of Catalysis

• Co-translational Glycosylation: The binding of an extended peptide in the ternary complex supports a mechanism where TMEM260 modifies nascent polypeptide chains before the IPT domain folds, likely occurring co-translationally in the ER lumen.
• Induced Fit: Upon acceptor peptide binding, the donor sugar (β-mannose) undergoes a ~60° rotation. This reorients the anomeric carbon toward the acceptor hydroxyl group (T822 in PLXNB2), facilitating nucleophilic attack.
• Catalytic Residues:
  • D441 (Rl domain): Identified as the general base that deprotonates the acceptor hydroxyl to trigger the reaction. Mutation (D441A) completely abolishes activity.
  • D52 (GT-C module): Essential for donor binding and orientation but not the direct catalytic base. It stabilizes the phosphate group of the donor.
  • Other residues: H67, R264, Y267, and R355 are critical for donor binding; mutations in the TPR "fingers" (N602, N638, N642, N680) severely impair acceptor recruitment.

C. Specificity and Disease Relevance

• Substrate Specificity: TMEM260 specifically targets IPT domains of plexins, cMET, and RON. It does not glycosylate cadherins (substrates of TMTC1–4) or α-dystroglycan (substrate of POMT1/2).
• Pathogenic Variant Interpretation: The structures provide a structural rationale for SHDRA syndrome variants:
  • Truncations removing the luminal domains (e.g., Q465*, Y470*) disrupt acceptor binding.
  • Missense mutations near the active site (e.g., C453R) cause steric clashes or destabilize the donor position.
  • Variants in the TPR domain (e.g., Y567Tfs*) impair substrate recruitment.

4. Significance

• First Structural Insight: This study provides the first atomic-resolution view of a mammalian O-mannosyltransferase, defining the structural basis for the initiation of O-Man biosynthesis.
• Mechanistic Clarity: It elucidates a "split active site" mechanism where the transmembrane domain handles the lipid donor and the luminal domain handles the protein acceptor, coupled by a conformational change (sugar rotation) upon substrate binding.
• Clinical Impact: The findings offer a structural framework for interpreting the pathogenicity of TMEM260 mutations associated with congenital heart and renal defects (SHDRA), potentially guiding future therapeutic strategies.
• Biological Paradigm: It establishes that TMEM260 acts on unfolded/extended peptides, suggesting a co-translational glycosylation mechanism that is crucial for the proper folding and trafficking of key cell-surface receptors involved in cell guidance and migration.